Last Updated: June 17, 2026

HYDROCHLOROTHIAZIDE W Drug Patent Profile

✉ Email this page to a colleague

« Back to Dashboard

When do Hydrochlorothiazide W patents expire, and what generic alternatives are available?

Hydrochlorothiazide W is a drug marketed by Watson Labs, Ivax Sub Teva Pharms, Pharmeral, and Roxane. and is included in fifteen NDAs.

The generic ingredient in HYDROCHLOROTHIAZIDE W is hydralazine hydrochloride; hydrochlorothiazide; reserpine. There are twenty-one drug master file entries for this compound. Additional details are available on the hydralazine hydrochloride; hydrochlorothiazide; reserpine profile page.

AI Deep Research

Questions you can ask:

What is the 5 year forecast for HYDROCHLOROTHIAZIDE W?
What are the global sales for HYDROCHLOROTHIAZIDE W?
What is Average Wholesale Price for HYDROCHLOROTHIAZIDE W?

Summary for HYDROCHLOROTHIAZIDE W

US Patents:	0
Applicants:	4
NDAs:	15

US Patents and Regulatory Information for HYDROCHLOROTHIAZIDE W

+ Get email alerts for changes to this table

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	HYDROCHLOROTHIAZIDE W/ HYDRALAZINE	hydralazine hydrochloride; hydrochlorothiazide	TABLET;ORAL	085373-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Pharmeral	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	085420-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ivax Sub Teva Pharms	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083568-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083666-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Roxane	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	084603-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Watson Labs	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	086331-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
Ivax Sub Teva Pharms	HYDROCHLOROTHIAZIDE W/ RESERPINE	hydrochlorothiazide; reserpine	TABLET;ORAL	083572-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.